OMC
INZY

Overbrook Management Corp’s Inozyme Pharma INZY Stock Holding History

Overbrook Management Corp’s Portfolio INZY Stock Details INZY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-219,326
Closed -$200K – 49
2025
Q1 		$200K Hold
219,326
– – 0.05% 46
2024
Q4 		$608K Hold
219,326
– – 0.13% 38
2024
Q3 		$1.15M Hold
219,326
– – 0.26% 35
2024
Q2 		$978K Hold
219,326
– – 0.25% 36
2024
Q1 		$1.68M Hold
219,326
– – 0.45% 32
2023
Q4 		$934K Hold
219,326
– – 0.19% 39
2023
Q3 		$921K Hold
219,326
– – 0.21% 36
2023
Q2 		$1.22M Hold
219,326
– – 0.29% 32
2023
Q1 		$1.26M Hold
219,326
– – 0.33% 32
2022
Q4 		$230K Buy
219,326
+150,000
+216% +$262K 0.07% 72
2022
Q3 		$186K Hold
69,326
– – 0.05% 76
2022
Q2 		$331K Buy
69,326
+52,600
+314% +$229K 0.1% 62
2022
Q1 		$68K Hold
16,726
– – 0.02% 93
2021
Q4 		$114K Hold
16,726
– – 0.02% 98
2021
Q3 		$194K Hold
16,726
– – 0.04% 85
2021
Q2 		$285K Hold
16,726
– – 0.06% 78
2021
Q1 		$331K Hold
16,726
– – 0.07% 68
2020
Q4 		$345K Hold
16,726
– – 0.08% 68
2020
Q3 		$440K Buy
+16,726
New +$415K 0.1% 82

Other funds holding INZY

BCM
Beryl Capital Management Redondo Beach, California $110M AUM 317.92% 1-Year Est. Return
PBPIA
Pivotal bioVenture Partners Investment Advisor San Francisco, California $280M AUM 181.4% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
OBAM
ODDO BHF Asset Management Paris, France $2.54B AUM 41.83% 1-Year Est. Return
TC
Trium Capital London, United Kingdom $163M AUM 45.8% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return

Overbrook Management Corp's INZY Position: Q2 2025 in Review

Overbrook Management Corp sold out of Inozyme Pharma (INZY) in Q2 2025, closing a stake of 219,326 shares — an estimated $200K sold.

Overbrook Management Corp first reported a position in INZY in Q3 2020 and held it in 19 quarters. The position peaked at $1.68M in Q1 2024. 86 funds tracked by Wall St. Rank hold INZY as of Q2 2025.

  • Overbrook Management Corp reported no remaining Inozyme Pharma position as of Q2 2025 after selling out during the quarter.
  • Overbrook Management Corp sold 219,326 Inozyme Pharma shares in Q2 2025, an estimated $200K.
  • Overbrook Management Corp first reported a position in Inozyme Pharma in Q3 2020 and held it in 19 quarters.
  • Overbrook Management Corp's Inozyme Pharma position peaked at $1.68M in Q1 2024.
  • 86 funds tracked by Wall St. Rank held Inozyme Pharma as of Q2 2025.

Based on Overbrook Management Corp's 13F filing for Q2 2025, filed 17 Jul 2025.